X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (48) 48
female (41) 41
oncology (41) 41
index medicus (39) 39
male (39) 39
chemotherapy (38) 38
aged (37) 37
middle aged (37) 37
cancer (30) 30
adult (25) 25
retrospective studies (19) 19
gastric cancer (18) 18
medicine & public health (18) 18
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
cancer research (16) 16
fluorouracil (16) 16
stomach cancer (16) 16
aged, 80 and over (15) 15
patients (15) 15
metastasis (14) 14
survival (14) 14
treatment outcome (14) 14
disease-free survival (13) 13
stomach neoplasms - pathology (12) 12
analysis (11) 11
colorectal cancer (11) 11
colorectal neoplasms - drug therapy (11) 11
stomach neoplasms - drug therapy (11) 11
surgical oncology (11) 11
trial (11) 11
5-fluorouracil (10) 10
adenocarcinoma (10) 10
care and treatment (10) 10
cisplatin (10) 10
oxaliplatin (10) 10
prognosis (10) 10
cisplatin - administration & dosage (9) 9
fluorouracil - administration & dosage (9) 9
gastroenterology & hepatology (9) 9
leucovorin (9) 9
neoplasm staging (9) 9
therapy (9) 9
tumors (9) 9
bevacizumab (8) 8
cancer therapies (8) 8
drug combinations (8) 8
neutropenia (8) 8
stomach neoplasms - mortality (8) 8
antimitotic agents (7) 7
antineoplastic agents (7) 7
capecitabine (7) 7
combination (7) 7
double-blind (7) 7
metastases (7) 7
multicenter (7) 7
neoplasms. tumors. oncology. including cancer and carcinogens (7) 7
pharmacology & pharmacy (7) 7
phase-iii (7) 7
prognostic factor (7) 7
research (7) 7
1st-line treatment (6) 6
antineoplastic agents - adverse effects (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
gastroenterology (6) 6
irinotecan (6) 6
japan (6) 6
pharmacology/toxicology (6) 6
s-1 (6) 6
survival rate (6) 6
trastuzumab (6) 6
adenocarcinoma - drug therapy (5) 5
antibodies (5) 5
cetuximab (5) 5
colorectal neoplasms - pathology (5) 5
esophageal cancer (5) 5
esophagus (5) 5
human epidermal growth factor receptor 2 (5) 5
leucovorin - administration & dosage (5) 5
open-label (5) 5
oxonic acid - administration & dosage (5) 5
squamous cell carcinoma (5) 5
tegafur - administration & dosage (5) 5
abdominal surgery (4) 4
adenocarcinoma - mortality (4) 4
adenocarcinoma - pathology (4) 4
adjuvant chemotherapy (4) 4
adjuvant treatment (4) 4
advanced gastric cancer (4) 4
antibodies, monoclonal - administration & dosage (4) 4
antineoplastic agents - therapeutic use (4) 4
apparatus for conversion between ac and ac, between ac and dc,or between dc and dc, and for use with mains or similar powersupply systems (4) 4
camptothecin - analogs & derivatives (4) 4
cancer patients (4) 4
chemotherapy, adjuvant (4) 4
circuit arrangements or systems for supplying or distributingelectric power (4) 4
clinical trials (4) 4
control or regulation thereof (4) 4
conversion of dc or ac input power into surge outputpower (4) 4
conversion or distribution of electric power (4) 4
development and progression (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


World Journal of Gastroenterology, ISSN 1007-9327, 2015, Volume 21, Issue 4, p. 1275
Journal Article
Gastric Cancer, ISSN 1436-3291, 1/2016, Volume 19, Issue 1, pp. 183 - 191
This study was conducted to investigate whether human epidermal growth factor receptor 2 (HER2) status, epidermal growth factor receptor (EGFR) status, and... 
Gastroesophageal junction cancer | Medicine & Public Health | Human epidermal growth factor receptor 2 | Gastroenterology | Abdominal Surgery | Oncology | Cancer Research | c-MET | Surgical Oncology | Gastric cancer | Epidermal growth factor receptor | 1ST-LINE TREATMENT | CLINICAL-FEATURES | LABEL PHASE-3 TRIAL | GROWTH-FACTOR RECEPTOR | OVEREXPRESSION | ONCOLOGY | DOUBLE-BLIND | CARCINOMAS | ESOPHAGOGASTRIC JUNCTION | GASTROENTEROLOGY & HEPATOLOGY | GENE COPY NUMBER | EXPRESSION | Proto-Oncogene Proteins c-met - metabolism | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Receptor, ErbB-2 - metabolism | Male | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Receptor, Epidermal Growth Factor - metabolism | Biomarkers, Tumor - metabolism | Esophageal Neoplasms - mortality | Female | Adenocarcinoma - genetics | Retrospective Studies | Stomach Neoplasms - genetics | Esophagogastric Junction - pathology | Oxonic Acid - administration & dosage | Stomach Neoplasms - drug therapy | Proto-Oncogene Proteins c-met - genetics | Esophageal Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Biomarkers, Tumor - genetics | Stomach Neoplasms - mortality | Drug Combinations | Adenocarcinoma - mortality | Immunohistochemistry | Cancer patients | Care and treatment | Chemotherapy | Patient outcomes | Analysis | Cytogenetics | Stomach cancer | Formaldehyde | Cancer
Journal Article
Gastric Cancer, ISSN 1436-3291, 11/2018, Volume 21, Issue 6, pp. 1050 - 1057
Although nivolumab showed survival benefit in patients with advanced gastric cancer (AGC) progressing after standard chemotherapy, there is a lack of data... 
Oxaliplatin | Medicine & Public Health | Gastroenterology | Abdominal Surgery | Prognostic factor | Oncology | Cancer Research | Surgical Oncology | Gastric cancer | Salvage therapy | GASTROESOPHAGEAL JUNCTION | TREATMENT OUTCOMES | OPEN-LABEL | OVARIAN-CANCER | ARBEITSGEMEINSCHAFT INTERNISTISCHE ONKOLOGIE | PHASE-III TRIAL | SUPPORTIVE CARE | ONCOLOGY | 3RD-LINE TREATMENT | DOUBLE-BLIND | 1ST-LINE THERAPY | GASTROENTEROLOGY & HEPATOLOGY | Leucovorin - administration & dosage | Salvage Therapy - adverse effects | Irinotecan - administration & dosage | Adenocarcinoma - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Fluorouracil - therapeutic use | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Adult | Female | Leucovorin - therapeutic use | Oxaliplatin - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Organoplatinum Compounds - therapeutic use | Stomach Neoplasms - mortality | Organoplatinum Compounds - adverse effects | Salvage Therapy - methods | Adenocarcinoma - mortality | Chemotherapy | Anemia | Analysis | Leucovorin | Stomach cancer | Cancer | Fluorouracil | 5-Fluorouracil | Multivariate analysis | Peripheral neuropathy | Patients | Cisplatin | Irinotecan | Platinum | Taxanes | Neutropenia
Journal Article
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 4/2018, Volume 23, Issue 2, pp. 275 - 280
Journal Article
The Lancet Oncology, ISSN 1470-2045, 06/2019, Volume 20, Issue 6, pp. 827 - 836
Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody–drug conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and... 
ANTIBODY-DRUG CONJUGATE | DIAGNOSIS | CARDIAC SAFETY | EMTANSINE | THERAPY | ONCOLOGY | ADENOCARCINOMA | HER2 | TUMORS | BREAST | Care and treatment | Research | Stomach cancer | Analysis | Oncology, Experimental | Cancer
Journal Article
世界胃肠病学杂志:英文版, ISSN 1007-9327, 2015, Volume 21, Issue 4, pp. 1275 - 1283
Journal Article
Case Reports in Oncology, ISSN 1662-6575, 04/2019, Volume 12, Issue 1, pp. 304 - 310
Here, we report the four cases with metastatic esophageal squamous cell carcinoma pretreated with standard chemotherapy who then received salvage-line... 
Case Report | Lymphatic system | Medical imaging | Metastasis | Radiation therapy | Patients | Cancer therapies | Stomach cancer | Ovarian cancer | Studies | Chemotherapy | Response rates | Health risk assessment | Esophageal cancer | Esophageal squamous cell carcinoma | Oxaliplatin | 5-Fluorouracil | FOLFOX | Cisplatin | Salvage chemotherapy
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 10/2016, Volume 21, Issue 5, pp. 890 - 898
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. TPS4131 - TPS4131
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2019, Volume 20, Issue 11, pp. 1506 - 1517
Chemotherapy for patients with advanced oesophageal squamous cell carcinoma offers poor long-term survival prospects. We report the final analysis from our... 
PROGNOSTIC-SIGNIFICANCE | ONCOLOGY | CANCER | DOCETAXEL | PD-L1 EXPRESSION | PACLITAXEL
Journal Article
by Fuchs, Charles S and Shitara, Kohei and Di Bartolomeo, Maria and Lonardi, Sara and Al-Batran, Salah-Eddin and Van Cutsem, Eric and Ilson, David H and Alsina, Maria and Chau, Ian and Lacy, Jill and Ducreux, Michel and Mendez, Guillermo Ariel and Alavez, Alejandro Molina and Takahari, Daisuke and Mansoor, Wasat and Enzinger, Peter C and Gorbounova, Vera and Wainberg, Zev A and Hegewisch-Becker, Susanna and Ferry, David and Lin, Ji and Carlesi, Roberto and Das, Mayukh and Shah, Manish A and Luft, Alexander V and Karaseva, Nina A and Kowalyszyn, Rubén Dario and Hernandez, Carlos Alberto and Csoszi, Tibor and De Vita, Ferdinando and Pfeiffer, Per and Sugimoto, Naotoshi and Kocsis, Judit and Csilla, Andràs and Bodoky, Gyorgy and Garnica Jaliffe, Georgina and Protsenko, Svetlana and Madi, Ayman and Wojcik, Elzbieta and Brenner, Baruch and Folprecht, Gunnar and Sarosiek, Tomasz and Peltola, Katriina Johanna and Bono, Peter and Ayala, Hubert and Aprile, Giuseppe and Gerardo, Cardellino Giovanni and Huitzil Melendez, Fidel David and Falcone, Alfredo and Di Costanzo, Francesco and Tehfe, Moustapha and Mineur, Laurent and García Alfonso, Pilar and Obermannova, Radka and Senellart, Hélène and Petty, Russell and Samuel, Leslie and Acs, Peter Istvan and Hussein, Maen Abdelkarim and Nechaeva, Marina N and Erdkamp, F.L.G and Won, Elizabeth and Bendell, Johanna Chock and Gallego Plazas, Javier and Lorenzen, Sylvie and Melichar, Bohuslav and Escudero, Miguel Angel and Pezet, Denis and Phelip, Jean-Marc and Kaen, Diego Lucas and Reeves, James A. Jr and Longo Muñoz, Federico and Madhusudan, Srinivasan and Barone, Carlo and Fein, Luis Enrique and Gomez Villanueva, Angel and Hebbar, Mohamed and Prausova, Jana and Visa Turmo, Laura and Vidal Barrull, Joana and Yilmaz, Mette Karen Nytoft and Beny, Alex and Van Laarhoven, H.M.W and DiCarlo, Brian Anthony and Esaki, Taito and Fujitani, Kazumasa and Geboes, Karen and Geva, Ravit and Kadowaki, Shigenori and Leong, Stephen and Machida, Nozomu and Raj, Moses Sundar and Ramirez Godinez, Francisco Javier and Ruzsa, Agnes and Ford, Hugo and Lawler, William E and Maisey, Nicolas Robert and Petera, Jiri and Shacham-Shmueli, Einat and Sinapi, Isabelle and ... and RAINFALL Study Grp and RAINFALL Study Group
The Lancet Oncology, ISSN 1470-2045, 03/2019, Volume 20, Issue 3, pp. 420 - 435
VEGF and VEGF receptor 2 (VEGFR-2)-mediated signalling and angiogenesis can contribute to the pathogenesis and progression of gastric cancer. We aimed to... 
EXPOSURE-RESPONSE | MULTICENTER | GASTROESOPHAGEAL JUNCTION | ANGIOGENESIS | ONCOLOGY | BEVACIZUMAB | COMBINATION | CANCER | EXPRESSION | CHEMOTHERAPY | ENDOTHELIAL GROWTH-FACTOR | Adenocarcinoma | Antimitotic agents | Care and treatment | Analysis | Clinical trials | Product development | Metastasis | Antineoplastic agents | Rain and rainfall
Journal Article
SCIENTIFIC REPORTS, ISSN 2045-2322, 07/2019, Volume 9, Issue 1, pp. 10526 - 10
Non-ampullary duodenal adenocarcinoma (NADC) is extremely rare. Little is known about its clinicopathological and molecular features or its management. Herein... 
ISLAND METHYLATOR PHENOTYPE | SURVIVAL | SMALL-BOWEL ADENOCARCINOMA | MICROSATELLITE INSTABILITY | MULTIDISCIPLINARY SCIENCES | DISTINCT | CARCINOMAS | ADENOMA | PATTERNS | CANCER | TUMORS | Adenocarcinoma | Genotype & phenotype | Phenotypes | Mucin | Immune checkpoint | Duodenum | PD-L1 protein | Microsatellite instability | Mutation | CpG islands
Journal Article